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Essentials: 
• Patients with cirrhosis have hemostatic changes, which may contribute to a risk of 
thrombosis. 
• This in vitro study compares clot formation and structure between patients and healthy 
subjects. 
• Clot formation is delayed in patients; ultimately, however, clot permeability is decreased.   
•  The thrombogenic structure of fibrin clots may contribute to the thrombotic risk in cirrhosis. 
 
Abstract 
Background & Aims: Patients with cirrhosis can be at risk of thrombotic complications due to an 
imbalance between hemostatic components. However, little is known on how the disease affects 
clot generation or how alterations in structure of fibrin clots may affect the hemostatic function of 
these patients.  
 
Methods: We investigated the formation and structure of clots generated with plasma and purified 
fibrinogen of 42 patients with cirrhosis. Clots generated with plasma and fibrinogen of 29 healthy 
volunteers were studied for comparison. Clot formation and structure were assessed by turbidity, 
permeation studies, confocal laser and SEM. The extent of fibrinogen oxidation was assessed by 
measuring carbonyl content of purified fibrinogen samples.  
 
Results: Tissue factor and thrombin-induced clotting of plasma was delayed in patients. The clotting 
rate was also decreased, but change in turbidity, fibrin density and fiber thickness were largely 
comparable to healthy volunteers. Conversely, clot permeability was significantly decreased in 
patients. When clots were generated with purified fibrinogen, similar differences in clot formation 
and structure were found as in plasma. The carbonyl content was increased in patient fibrinogen and 
correlated with disease severity and clot permeability.  
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Conclusions: Delayed clot formation in cirrhosis ultimately results in decreased clot permeability. 
Similar alterations in clots generated with purified fibrinogen suggest that modifications of the 
molecule are (partly) responsible. Taken together, these findings are indicative of hypercoagulable 
features of clots of patients with cirrhosis, which may explain the increased risk of thrombosis 
associated with the condition. 
 
Keywords: fibrinogen, hemostasis, liver cirrhosis, oxidative stress, thrombosis. 
Introduction 
The clinical consequences of hemostatic disorders in patients with chronic and acute liver diseases 
can vary significantly from bleeding to thrombosis, and the conceptual understanding of the 
underlying mechanisms have changed considerably over the last decade. The latest proposed 
paradigm is that the combined effects of the hemostatic changes in cirrhosis produce a rebalanced, 
yet precarious hemostatic system, which may easily tip toward either a bleeding diathesis or a 
thrombotic tendency [1,2]. It has now been well established that patients with cirrhosis and 
abnormal routine coagulation tests do not necessarily have a bleeding tendency, and that 
thrombotic complications may occur in these patients [3]. In addition, an increasing number of 
studies suggest a link between thrombosis and progression of liver disease [4,5]. Probably the most 
striking example is a recent prospective, randomized study demonstrating that low molecular weight 
heparin therapy, aimed at preventing portal vein thrombosis, also reduced hepatic decompensation 
and mortality in a cohort of patients suffering from moderate-to-severe cirrhosis [6]. 
  
   The clinical concept of thrombosis as an important complicating factor of cirrhosis is 
supported by evidence from the laboratory. In vitro studies have demonstrated a disease stage-
dependent decrease in the capacity of plasma of cirrhotic patients to regulate thrombin generation 
[7,8]. In further studies, high levels of the platelet-binding protein Von Willebrand factor were found 
to result in a supranormal primary hemostatic function in these often thrombocytopenic patients 
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[9,10]. Recent studies have highlighted abnormal fibrin clot structure and function as a potential risk 
factor for thrombosis. Acquired or inherited changes in fibrin structure have been associated with 
venous and arterial thromboembolic events [11-15]. Interestingly, in spite of current advancements 
in our understanding of the net effects of the changes in primary and secondary hemostasis in 
chronic liver failure, little is known on the generation and structure of fibrin clots in these patients.  
Studies published more than three decades ago suggested qualitative defects in the fibrin 
clot in patients with cirrhosis, specifically, increased glycosylation of fibrinogen. This hypersialated 
fibrinogen displayed delayed fibrin polymerization [16,17]. However, in studies conducted by our 
group [18,19] a normal capacity to generate fibrin clots was found when using plasma of cirrhotic 
patients indicating that, under more physiological circumstances, qualitative defects in fibrinogen 
may not necessarily translate to a reduced clot function.  
 
To elucidate the net effect of changes in fibrinogen in cirrhosis, we studied the clot 
generation process as well the structural properties of clots from a cohort of patients with cirrhosis 
of various severity and etiology. We examined clots made with plasma as well as with fibrinogen 
purified from the patients to determine whether changes in plasma composition or in fibrinogen 
itself underpin any alterations in fibrin function and structure. Finally, we investigated oxidative 
modifications of fibrinogen, which were recently shown to alter both the structure and function of 
the molecule [20]. Indeed, as fibrinogen is one of the most abundant plasma proteins, it is a likely 
target for oxidative stress [21], one of the hallmarks of chronic liver disease [22-25]. 
 
Patients and Methods 
Patients 
Forty-two patients with a clinical diagnosis of cirrhosis were recruited from the Hepatology 
outpatient clinic or ward of the University Medical Center Groningen between August 2012 and April 
2013. These patients were classified according to the Child-Pugh classification [26]. Exclusion criteria 
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were a documented history of congenital coagulation disorders, recent viral infection (<2 weeks), 
use of anticoagulant drugs in the past 10 days, pregnancy, HIV positivity, and transfusion with blood 
products within past 7 days. Plasma samples from 29 healthy volunteers from our laboratory (nine 
males and twenty females, mean age 34 ±12 years, and two current smokers) were used to establish 
reference values. Exclusion criteria for the volunteer group were documented history of congenital 
coagulation disorders, documented history of hepatic disease, recent viral infection (<2 weeks), use 
of anticoagulant drugs in the past 10 days, pregnancy, and HIV positivity. The study protocol 
conformed with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the 
medical ethics committee of the University Medical Center Groningen, Groningen, The Netherlands. 
Written informed consent was obtained from each subject before inclusion. Details of blood sample 
withdrawal and processing have been described previously [27]. 
 
Fibrinogen levels  
Fibrinogen levels in plasma of patients and healthy volunteers were determined on an ACL TOP 300 
analyzer using reagents from Instrumentation Laboratory (Breda, The Netherlands) according to the 
manufacturers instructions. 
 
Purification of Fibrinogen and addition of Factor XIII 
Fibrinogen was purified from the plasma of patients and volunteers as described [28]. In short, 
fibrinogen was purified from plasma using IF-1 (calcium dependent antibody) affinity 
chromatography, during which contaminating proteins were eliminated from the fibrinogen with 
washing buffers containing 0.3 and 1M NaCl respectively, prior to elution with EDTA. We have 
previously shown that this method effectively eliminates any Factor (F) XIII bound to the fibrinogen 
[29], and hence the purified fibrinogen preparations were FXIII-free prior to addition of exogenous 
FXIII at the controlled concentration of 7.3 µg/ml. Purity of the fibrinogen samples was examined by 
reducing sodium dodecyl sulfatepolyacrylamide gel electrophoresis using a Mini-Protean system 
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with 4-20% Bis-Tris gradient TGX gels (Bio-Rad, Hercules, CA). Gels were run at 80 V for 10 min and 
then at 150V for 1 h 15 min in MES buffer (Life Tech., Carlsbad, CA), stained with coomassie blue 
solution and scanned using a CanoScan 8800 F (Canon, Tokyo, Japan).  
 
Turbidity assays 
Fibrin clot formation in plasma or purified fibrinogen was studied by turbidity analysis as described 
[30]. Investigated parameters were clotting time (time to ½ max OD in min), clotting rate (mOD/min 
at ½ max OD), and change in turbidity of the clot defined as the difference between the OD at the 
start and maximum OD. Triplicates were measured for each sample and averaged.  
 
Thrombin generation assay 
Thrombomodulin-modified thrombin generation tests were performed by calibrated automated 
thrombography as previously described  [27].  
 
Clot lysis assay 
Lysis of a tissue factorinduced clot by exogenous t-PA was studied by monitoring changes in 
turbidity during clot formation and subsequent lysis essentially as described previously [31].  
 
Clot Permeation 
Plasma and purified fibrinogen clotting mixtures for permeation measurements were prepared as 
described [28,32].Immediately after mixing, 100 µL of the clotting mixture was carefully transferred 
to a 4.5 cm plastic tip with a roughened interior surface, which was cut off from a 1 ml Costar 
pipette tip. The clot mixture was left to consolidate in a humidified chamber at room temperature 
for 2 h. The plastic tip was then connected through a flexible silicon tube to a syringe containing TBS 
with a 4-cm pressure drop. Upon connection, TBS was left to permeate through the fibrin clot 
network for 1.5 h to wash any other, non-fibrin, plasma components, such as albumin. Then, 
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measurements were performed in duplicate by collecting drops passing through the clot in a pre-
weighed eppendorf tube and weighing the total volume of liquid in the tube every 30 minutes for 
two hours. These measurements were averaged. Clot permeability was ultimately determined by 
calculating the Darcys constant (Ks), which is a measure of the pore size of the fibrin network 
through which liquid may pass, as described [33].  
 
Laser scanning confocal microscopy  
Plasma and purified fibrinogen (1 mg/mL) clots for laser scanning confocal microscopy were 
generated as described [34]. To visualize the clots, AlexaFluor488 FITC labeled fibrinogen (Life Tech, 
Carlsbad, CA; 50 µg/mL final concentration in plasma and 25 µg/mL in purified experiments) was 
added during clot formation. Clots were left to form at room temperature in a dark humidified 
chamber for 1 h. Laser scanning confocal microscopy (LSCM) was then performed using an upright 
Zeiss LSM-510 META Axioplan2 confocal microscope (Carl Zeiss Ltd, Welwyn Garden City, UK) fitted 
with a x63 numerical aperture 1.4 oil immersion objective. The scan format was 512x512 pixels with 
the pinhole set to one Airy unit to obtain maximum resolution in the z-plane. Single optical sections 
of 230/230µm (x/y) were taken at three different areas throughout the clot to visualize the fibrin 
network. Fiber density of the clot was analyzed using ImageJ software (National Institute of Health, 
Bethesda, MD). Fiber density was determined by an in-house designed macro plug-in, which places a 
10 x 10 lines grid on individual images and computes the number of fibers intersecting these lines. 
Fiber densities of three different micrographs per sample were averaged.  
 
Scanning electron microscopy 
Plasma clots from 5 patients (3 Child score A and 2 Child B) and 5 healthy individuals were generated 
and prepared for scanning electron microscopy as described [35]. Subjects were chosen based on 
clot permeability values closest to the median of their respective groups. Each clot was imaged in 
five different areas at 20 x 10
3
 magnification using a FEI Quanta 200 FEGSEM (FEI, Hillsboro, OR). 
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Average fiber diameters were measured from 50 random fibers in each sample using ImageJ 
software.  
 
Fibrinogen ɶ levels in plasma 
Fibrinogen ɶ antigen levels were measured using an in-house ELISA based on the method of Uitte de 
Willige [36].  
 
Fibrinogen carbonyl content and plasma malondialdehyde levels   
Carbonylation of purified fibrinogen samples was quantified using a commercially available ELISA kit 
(Enzo Life Sciences, Farmingdale, NY) following the manufacturers instructions. Malondialdehyde 
(MDA) levels were estimated in plasma as an indication of lipid peroxidation by measuring 
thiobarbituric acid reactive substances (TBARS) as described [37].  
 
Statistical Analysis  
Statistical analysis was performed with the Graphpad InStat (San Diego, CA) software package. 
Continuous variables are expressed as the mean±SD or median and range. Categorical data are 
expressed as numbers and percentage. Continuous data were tested for normality and analyzed by 
Unpaired t-test or the Mann-Whitney U test, as appropriate, for comparison between two groups, 
and by ANOVA with Dunnetts post-test or by Kruskal-Wallis test with Dunns post-test for multiple 
group comparisons. In these analyses, values were compared with healthy volunteers' values. 
Correlations were examined by calculating Pearsons Rho. A P value less than .05 was considered 
statistically significant. 
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Results 
Demographic, laboratory, and clinical characteristics of patients with cirrhosis and healthy 
individuals. Patient demographics, including clinical data and laboratory test results are presented in 
Table 1. Median fibrinogen levels were 2.7 g/L in patients with Child A, 1.8 g/L in Child B and 1.7 g/L 
in Child C cirrhosis. Median fibrinogen levels were 2.6 g/L in healthy individuals. 
    
Prolonged clotting time and decreased clotting rate, but normal optical density of clots generated 
with plasma of patients with cirrhosis. Turbidimetric analysis was used to determine fibrin 
polymerization. As shown in Fig. 1A and 1B, the time to generate a fibrin clot was overall longer 
when using plasma of patients with cirrhosis (6.1 min [4.5-9.5] (median [range]) when activated with 
TF and 1.4 min [1.1-2.2] for thrombin-mediated activation) when compared with the reference (5.1 
min [3.9-7.3] and 1.2 min [0.9-1.4]). Clotting times in patients or healthy volunteers did not correlate 
with fibrinogen levels (data not shown). The clotting rate was decreased in patient plasma (median 
rate 0.3 mOD/min [0.2-0.9] for TF and 0.2 mOD/min [0.1-0.2] for thrombin-mediated activation) 
when compared to the healthy volunteer group in which the clotting rate was 0.4 mOD/min [0.2-0.7] 
(p<0.01) and 0.3 mOD/min [0.1-0.4] (p<0.05) for TF and thrombin-mediated activation, respectively 
(Figs. 1C and 1D). The generally decreased clotting rate appeared largely the result of significant 
decreases in the Child B and C subgroups. Clotting rates correlated well with fibrinogen levels within 
patients (r=0.86, p<0.01 for TF, and r=0.35, p<0.05 for thrombin-mediated activation) and volunteers 
(r=0.9, p<0.01 for TF and r=0.58, p<0.01, for thrombin). Thrombin generation assay (TGA) 
parameters on the other hand did not correlate with turbidity parameters in cirrhosis (p>0.05 for 
every correlation coefficient). In Figs. 1E and 1F, it is demonstrated that, on average, the change in 
absorbance after fibrin polymerization was comparable between patients and healthy volunteers 
regardless of the mode of activation, although the change in absorbance was slightly lower than 
volunteers in the Child B and C groups.  
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Decreased permeability of clots generated with plasma of patients with cirrhosis. We tested the 
permeability of clots generated with thrombin. Clots were perfused with TBS and the total volume of 
fluid passing through the clot in a given time period was measured. A less permeable clot allows less 
liquid to pass through, resulting in a lower permeability coefficient Ks. As shown in Fig. 2, clots 
generated with plasma of patients were significantly less permeable (median Ks 6.5x10
-9  
[1.9x10
-9
-
1.5x10
-8
]) when compared to clots from healthy volunteers (median Ks 9.6x10
-9
 [6.0x10
-9
-2.4x10
-8
] 
(p<0.01). Clot permeability negatively correlated with fibrinogen levels in patients, albeit moderately 
(r=-0.56, p<0.01). Clot permeability also negatively correlated with clot lysis time in patients (-0.53, 
p<0.01). TGA parameters did not correlate with clot permeability in cirrhosis (r=0.18 for Endogenous 
Thrombin Potential (ETP); r=-0.04 for Velocity index; r=-0.14 for Lag time; r=-0,14 for time-to-peak 
(p>0.05 for every correlation coefficient)). 
 
Normal Fibrinogen ɶ levels in plasma of patients with cirrhosis. Previous studies have shown that 
the proportion of fibrinogen ɶ can influence fibrin clot structure in vitro and in plasma [38,39]. In Fig 
3A, it is shown that fibrinogen ɶ are decreased in cirrhosis, however, when adjusted for fibrinogen 
levels as shown in Fig 3B, the proportion of fibrinogen ɶ in plasma was comparable between 
patients and healthy volunteers (139 ʅg per mg fibrinogen [50-453] versus 171 ʅg/mg [87-341] 
(p>0.05)). These data suggest that the observed changes in permeability and clot structure are not 
caused by any changes in fibrinogen ɶ in this study. 
   
Normal fibrin density and fiber diameter within clots generated with plasma of patients with 
cirrhosis. Fibrin fiber density and diameter was examined by laser scanning confocal microscopy 
(LSCM) and scanning electron microscopy (SEM), respectively. A representative LSCM image of a 
section of a fibrin clot generated with plasma of patient with Child B cirrhosis is shown in Fig. 4A. It 
indicates a normal fiber density in comparison with a representative healthy volunteer clot (Fig. 4B). 
Fiber density was quantified in Fig. 4C and demonstrated similar median fiber densities in patients 
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and healthy volunteers, although the fiber density appeared increased in the Child A cirrhosis group 
(2.45 Fiber/10µm [0.97-8.18] vs. 1.86 [0.66-8.14] in volunteers (p>0.05). The fiber diameter also 
appeared similar in both groups with an average diameter of ~140 nm per fiber, as demonstrated in 
Fig. 4D. Figs. 4E and 4F show comparable SEM images from individual fibrin fibers within sections of 
clots of a patient with Child B cirrhosis and a healthy volunteer, respectively.  
 
Prolonged clotting time, but normal clotting rate and optical density of clots generated with 
fibrinogen purified from patients with cirrhosis. As shown in Fig. 5A, the clotting time at equal 
fibrinogen concentration was prolonged in the patient group (2.8 min [2.3-3.7] when compared with 
healthy individuals in which the median was (2.5 min [2.3-3.1] (p<0.01). On the other hand, clotting 
rates as well as changes in absorbance during clotting were similar between patients and healthy 
volunteers, as demonstrated in Figs. 5B and 5C, respectively.  
   
Decreased permeability, but normal fiber density of clots generated with fibrinogen purified from 
plasma of patients with cirrhosis. In Fig. 5D, it is shown that clots generated at an equal 
concentration of fibrinogen were significantly less permeable in the patient group (median Ks 
6.1x10
-9 
[1.7x10
-9
-1.1x10
-8
]) when compared to clots of healthy volunteers (median Ks 8.1x10
-9
 
[4.9x10
-9
-1.4x10
-8
] (p<0.01). On the other hand, Fig. 5E indicates a normal fiber density of clots 
generated with fibrinogen of patients in comparison with volunteers. This is visualized in Fig. 5F with 
representative LSCM images of the fibrin mesh in clots of a patient and a healthy volunteer, 
respectively.   
 
Increased carbonyl content of fibrinogen purified from plasma of patients with cirrhosis. Fig. 6 
shows a significantly increased carbonyl content of fibrinogen isolated from patients when 
compared with healthy volunteers (median 2.2 nmol/mg [1.4-4.3] versus 1.5 nmol/mg [1.3-2.6], 
respectively (p<0.01). The extent of carbonylation in patients was associated with disease severity 
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and inversely correlated with clot permeability. The correlation coefficient was r=-0.46; p<0.05 for 
patients combined, r=-0.69 for the Child A group (p<0.01), r=-0.65 for Child B (p<0.01) and -0.14 for 
Child C (p>0.05). In addition, it positively correlated with serum MDA levels (r=0.35, p<0.5).  
Smoking or co-morbidities in the patient group are not associated with changes in clot 
permeability. We explored possible relationships between the permeability of clots generated with 
plasma and smoking, co morbidities and complications in the patient group. We found no 
differences in clot permeability between smokers and non-smokers or between patients with and 
without significant co-morbidity (data not shown). Also, no correlation was found between smoking 
frequency and MDA levels or carbonyl content of fibrinogen (r=-0.05, p>0.05 and r=0.04, p>0.05, 
respectively).  A relationship between clot permeability and thrombosis could not be demonstrated 
as only three events of thrombotic complications were recorded. Clot permeability in patients with a 
history of bleeding (mostly variceal bleeds) was not different from patients who had not experienced 
a bleeding event (Ks 6.5x10
-9 
[2.0x10
-9
-1.2 x10
-8
 vs. 6.7x10
-9 
[1.2x10
-9
-1.5x10
-8
] (p>0.05; data not 
shown). 
 
 
Discussion  
This study of fibrin clot structure in patients with cirrhosis shows alterations in clotting kinetics and 
fibrin structure. We found that although the kinetics of clot formation were decreased in cirrhosis, 
the clots were ultimately less permeable. This implies that decreased levels or functional defects in 
fibrinogen in cirrhosis do not necessarily translate into a reduced clot function promoting a risk of 
bleeding. On the contrary, a decrease in clot permeability may rather indicate an increased risk for 
thrombosis. Indeed, previous studies have shown decreased fibrin clot permeability to be associated 
with both arterial and thrombotic diseases [11-15]. In turn, this study supports a potential 
prothrombotic role of fibrin clots in patients with acute and chronic liver failure opposing the effects 
of reduced production of coagulation factors [40]. The prolonged clotting times and decreased clot 
permeability in both plasma and samples of purified fibrinogen suggest that structural alterations of 
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the fibrinogen molecule itself underpin the changes in fibrin structure. We detected an increase in 
the carbonyl content of fibrinogen isolated from patients indicating that oxidative modifications of 
the protein may be responsible for the prolonged clotting time and reduced clot permeability. 
  
We and others are systematically studying consequences of hemostatic defects in patients 
with cirrhosis. These studies have shown that primary and secondary hemostasis remain functional, 
and are perhaps even hyperreactive. We first demonstrated that elevated levels of the platelet 
adhesive protein von Willebrand factor (over)compensate for abnormalities in platelet number and 
function in patients with cirrhosis [9]. Others have subsequently demonstrated that the thrombin 
generating capacity in cirrhosis was intact, despite prolongations in routine laboratory tests of 
coagulation such as the prothrombin time (PT) or international normalized ratio (INR) and activated 
partial thromboplastin time (APTT) [41]. The data presented here suggest that the final stage of 
blood coagulation, the formation of a fibrin clot, is also in a rebalanced, perhaps overcompensated 
state. Despite reduced fibrinogen levels, the fibrin clot is less permeable (and therefore more 
resistant to permeation of fibrinolytic enzymes into the clot) compared with healthy individuals. The 
delayed clot formation is in agreement with previous studies in cirrhosis demonstrating that 
increased fibrinogen glycosylation results in defects in fibrin polymerization [16,17]. Alternatively, 
slower fibrin polymerization may result from oxidative modifications of the fibrinogen molecule [42-
44] and since fibrinogen oxidation can also promote a less permeable fibrin structure [44] it is a 
potential mechanism to explain our findings.  
  
Fibrin network production is essential for hemostasis. During the course of fibrin 
polymerization, fibrinogen molecules assimilate to form a 3-dimentional fibrin network. Clot stability 
is determined by the structure of the network, which is characterized by the density and diameter of 
fibers, number and nature of the branch points, and number and size of pores [45]. In turn, these 
structural features may vary depending on a myriad of factors controlling the clot generation 
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process. These include fibrinogen structure and concentration, available concentrations of pro- and 
anticoagulants, which in turn dictate the thrombin generation potential, and local cellular effects 
[46]. By breaking down the process in individual steps we provided insight into how clotting 
dynamics are affected in cirrhosis. First, we observed that clotting rates of turbidity assays triggered 
with tissue factor or thrombin are sensitive to the level of fibrinogen in cirrhosis, but less so in the 
thrombin triggered turbidity assays. This may be explained by the fact that the effects of fibrinogen 
on thrombin generation [47] are effectively by-passed in the latter and the effect of fibrinogen 
concentration on clotting rates becomes less dominant. Secondly, we observed increased clotting 
times when the plasma of patients was activated with either tissue factor or thrombin, independent 
of the level of fibrinogen. This demonstrated that the complex alterations in coagulation factors 
associated with cirrhosis were not the only determinant affecting clot generation, and suggested the 
presence of a defect in the fibrinogen to fibrin conversion step. This was subsequently confirmed 
when the clotting time remained abnormal when using fibrinogen isolated from patients. As 
fibrinogen, Factor XIII and thrombin had been adjusted to equal levels between patients and healthy 
volunteers, the most likely explanation for the rate-limiting step in fibrin polymerization was an 
alteration in one or more structural properties of fibrinogen.   
 
A recent review on oxidative modifications of fibrinogen revealed different, even opposing effects, 
depending on the modified site [20]. Here we demonstrated a defect in clot formation kinetics 
resulting in less permeable clots ultimately, which correlated with an increase in fibrinogen carbonyl 
content. Interestingly, apart from the changes in clot permeability, other investigated structural 
parameters were normal (i.e., change in absorbance, fibrin density and fiber diameter) suggesting 
that the changes in the fibrinogen molecule in patients with cirrhosis only affect fibrin metastructure 
by reducing pore size or number. This is in contrast with results of turbidity studies conducted by 
Paton et al. [48], who demonstrated a negative association between fibrinogen carbonyl content 
and change in absorbance and which may be explained by different experimental conditions, the 
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most prominent being the lack of added calcium, while fibrinogen is well known to contain 
functional calcium binding sites. 
The lack of association between permeability and other structural parameters, such as fibrin 
density, may be explained by the fact that it is a combination of modest structural changes that 
accounts for changes in metastructure, the sum of which leads to a significantly decreased clot 
permeability. Furthermore, the relationship between permeation and fiber diameter may be 
influenced by changes in the intrafibrillar composition of fibrin fibers such as protofibril packing [49]. 
Also, permeability may be governed by more than just structure. Alterations such as oxidation and 
sialyation might lead to reduced permeability (e.g. by charge/hydrophobicity effects), but not to 
changes in structure. A similar study using a larger cohort will shed more light on this apparent 
discrepancy between permeability and other structural parameters in cirrhosis. A limitation of the 
study is that we cannot rule out that other structural modifications of fibrinogen also may have 
contributed to a certain extent in the remodeling of the fibrin metastructure, although we did not 
find increased fibrinogen gamma prime levels in our patients which are thought to prompt the 
formation of more thrombogenic clots [50]. Nonetheless, the similarly decreased permeability of 
clots generated with plasma and purified fibrinogen shows that the procoagulant effects associated 
with changes in fibrinogen structure persist under more physiological conditions and therefore 
probably translate to the in vivo situation.  
 
In recent years, there has been a major shift in our understanding of the clinical 
consequences of cirrhosis-associated coagulopathy. Expert opinion suggests that bleeding in many 
(surgical) cases is more likely due to hemodynamic changes in patients with chronic liver disease 
than to an underlying hemostatic disorder [51]. It also suggests that patients with cirrhosis are not 
auto-anticoagulated: they are not protected from thrombotic events even when routine tests of 
coagulation including PT or INR and APTT are prolonged, or when platelet numbers are low [52]. In 
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fact, it is increasingly recognized that thrombosis can be a major complicating factor in cirrhosis and 
may even contribute to disease progression [53,54]. We propose that, similarly to cohorts of 
smokers, patients with venous thromboembolism and patients with cardiovascular diseases who 
show comparable changes in fibrinogen and fibrin clot structure [55-58], enhanced fibrinogen 
carbonylation in patients with cirrhosis prompts the formation of clots with a procoagulant 
structure. In turn, this contributes to the thrombotic risk in these patients. The mechanism involved 
in an increased thrombotic risk in patients with less permeable clots may be a reduced disposition of 
clots to lysis as evidenced by the negative correlation between permeability and clot lysis time 
demonstrated here. This is the result of both an increased stability of clot structure and reduced 
capacity of fibrinolytic enzymes to penetrate through the clot [14,59,60]. Ultimately, this may 
facilitate the development of dangerous thrombi in the (micro)vasculature. Interestingly, clot 
permeability was not linked to bleeding in the present study. Larger studies will be needed to 
demonstrate associations with thrombotic events.  
 
In conclusion, the dysfibrinogenemia associated with liver disease has been functionally 
characterized by an increased clotting time due to impaired fibrin polymerization and was 
traditionally associated with a risk of bleeding. For the first time, we have shown that impaired clot 
formation in cirrhosis does not necessarily translate in a decreased hemostatic capacity as clots of 
patients have thrombogenic features evidenced by reduced permeability. We have attributed this to 
procoagulant changes in fibrin metastructure resulting from excessive carbonylation of fibrinogen 
and which appears to compensate for a decrease in fibrinogen level. This study provides further 
evidence of a rebalanced hemostatic function in patients with cirrhosis and adds to an increasing 
number of epidemiological, clinical and in vitro studies of the presence of an elevated thrombotic 
risk as a consequence of the condition.   
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 Characteristics Child A (n=20) Child B (n=15) Child C (n=7) Patients combined (n=42) Healthy individuals (n=29)
Value Value Value Value Value
 Age, years 54 (11) 49 (13) 49 (14) 51 (12) 32 (9)
 Male sex 8 {40} 9 {60} 5 {71} 22 {52} 12 {41}
 BMI, kg/m2 25 (4) 29 (5) 30 (6) 27 (5) 23 (3)
 Smokers 12 {60} 2 {13} 2 {29} 16 {38} 1 {3}
 Cigarettes/day 5 (5) 2 (5) 2 (4) 3 (5) 2
 Etiology
Alcohol abuse 9 {45} 4 {27} 6 {86} 19 {45}
NAFLD 2 {10} 3 {20} 0 5 {12}
PSC 3 [15} 1 {6} 0 4 {10}
AIH 2 {10} 2 {8} 0 4 {10}
Combination 2 {10} 1 {6} 0 3 {7}
HCV 0 2 {13} 0 2 {5}
Indeterminate 0 1 {7} 1 {14} 2 {5}
Hemochromatosis 0 1 {7} 0 1 {2}
Wilson's disease 1 {5} 0 0 1 {2}
PBC 1 {5} 0 0 1 {2}
 Laboratory blood tests
AST, U/L 48 [36-70] 63 [48-96]  70 [46-81] 56 [43-80]
ALT, U/L 36 [28-64] 32 [26-60] 29 [19-42] 34 [26-59]
ALP, U/L 133 [76-191] 112 [92-212] 108 [88-146] 118 [90-172]
GGT, U/L 112 [56-216] 94 [52-215] 46 [23-91] 93 [48-197]
LDH, U/L 180 [152-247] 205 (182-235) 220 (200-353) 199 [165-249]
Total bilirubin, ʅmol/L 21 [8-26] 46 [25-51] 70 [36-121] 26 [16-51]
Albumin, g/L 36 [31-43] 33 [31-35] 28 [26-31] 33 [30-41]
Fibrinogen, g/L 2.7 [2.1-3.7] 1.8 [1.6-2.6] 1.7 [1.5-2.3] 2.2 [1.6-3.0] 2.6 [1.7-3.6]
INR 1.1 (0.2) 1.3 (0.2) 1.5 (0.2) 1.3 [0.2]
Platelet count, x109/L 121 [93-205] 76 [48-133] 75 [44-114] 104 [58-159]
Hemoglobin 8.1 (1.0) 7.4 (1.0) 6.3 (1.1) 7.6 (1.2)
WBC, x109/L 7.2 (3.3) 4.6 (2.5) 7.3 (3.5) 6.3 (3.2)
CRP, mg/L <5 [<5-15] <5 [<5-14] 7 [<5-18] 6 [<5-15]
Sodium, mmol/L 138 (3) 139 (3) 132 (2) 137 (4)
Potassium, mmol/L 3.6 (0.4) 4.0 (0.5) 4.1 (0.5) 4.0 (0.4)
Creatinine, ʅmol/L 58 [50-79] 68 [62-91] 85 [47-118] 68 [54-84]
Urea, mmol/L 4.7 [3.8-6.4] 5.5 [3.5-9.0] 4.5 [4.4-9.4] 5.0 [3.8-7.5]
Glucose, mmol/L 7.6 (3.2) 6.4 (2.2) 5.6 (0.6) 6.7 (2.5)
MDA 3.5 [1.8-8.9] 4.5 [3.0-6.8] 5.9 [3.5-10.7] 4.3 [1.8-10.7] 2.8 [2.1-4.8]
Hemostasis tests
Clot lysis time, min 56 [40-105] 37 [30-65] 40 [30-52] 48 [30-105] 55 [42-72]
TGA, ETP 780 [460-1683] 906 [607-1111] 838 [838-1030] 884 [460-1683] 816 [579-1262]
TGA, Vel Index 63 [26-121] 85 [69-121] 77 [41-97] 61 [26-121] 77 [26-136]
TGA, Lag time 1.7 [1.2-2] 1.3 [1.3-2.0] 1.4 [1.1-5] 1,7 [1.1-2.0] 1.6 [1.3-2.0]
 TGA, Peak time 145 [97-248] 182 [139-251] 144 [101-174] 167 [97-248] 162 [102-241]
 Complications
Ascites 5 {25} 9 {81} 7 {100} 21 {50}
Encephalopathy 2 {10} 1 {6} 5 {71} 8 {19}
Thrombosis 1 {5} 1 {6} 1 {14} 3 {7}
Bleeding (mostly variceal) 5 {25} 5 {30} 2 {29} 12 {29}
 Co-morbidities
Hypertension  4 {20} 4 {27} 0 8 {19}
AP 1 {5} 1 {6} 0 2 {5}
DM II 6 {30} 2 {13} 1 {14} 9 {21}
Chronic kidney disease 1 {5} 1 {6} 0 2 {5}
Chronic lung disease 2 {10} 0 0 2 {5}
Chronic bowel disease 2 {10} 1 {6} 0 3 {7}
Malignancy 1 {5} 2 {13} 0 3 {7}
Abbreviations: AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AP, angina pectoris; AST, aspartate aminotransferase; 
BMI, body mass index; CRP, C-reactive protein; DM II, diabetes mellitus II; ETP, endogenous thrombin potential; GGT, gamma-glutamyl transpeptidase; HCV, 
hepatitis C virus; INR, international normalized ratio; LDH, lactate dehydrogenase; MDA, malondialdehyde; PBC, primary biliary cirrhosis; PSC, primary 
sclerosing cholangitis; TGA, thromboelastography. Data are presented as mean (SD), numbers {percentages} or medians [IQR].
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Table 1. Demographic, Laboratory, and Clinical Characteristics of the Study Cohorts.  
Figure 1. Turbidity parameters of clots generated from plasma of patients with cirrhosis and healthy 
volunteers. (A) Clotting time upon activation with 5pM TF, and (B) 0.5 IU/ml thrombin. (C) Clotting rate 
upon activation with TF and (D) thrombin. (E) Changes in optical density of clots upon activation with TF and 
(F) thrombin. Horizontal bars represent medians. Asterisks indicate significant differences in comparison 
with healthy volunteer values.  *P<0.05; **P<0.01.  
Figure 2. Permeability of clots generated with plasma of patients with cirrhosis and healthy volunteers.  The 
permeability coefficient Ks was calculated following Darcys Law. Horizontal bars represent medians. 
Asterisks indicate significant differences in comparison with healthy volunteer values. **P<0.01.  
Figure 3. Fibrinogen ɶ levels in plasma of patients with chronic liver disease and healthy volunteers. (A) 
Absolute Fibrinogen ɶ levels and (B) Fibrinogen ɶ levels relative to total fibrinogen. Levels are expressed in 
microgram per milliter and per milligram fibrinogen. Horizontal bars represent medians.   
Figure 4. Representative images of sections of clots generated with plasma of patients with cirrhosis and 
healthy volunteers. (A) Fibrin mesh in clot of a patient with Child B cirrhosis and (B) of a healthy volunteer 
clot visualized by laser scanning confocal microscopy (original magnification x630). (C) Fiber density in the 
fibrin mesh was quantified by counting the number of fibers crossing an arbitrary line drawn through the 
section. Density is expressed as the number of fibers per 10 ʅm. (D) Fibrin fiber thickness was quantified by 
measuring the diameter of individual fibers. The diameter is expressed in nanometers. Horizontal bars 
represent medians. (E) Fibrin mesh in a clot of a patient with Child B cirrhosis and (F) of a healthy volunteer 
clot visualized by SEM (original magnification x20.000).  
Figure 5. Functional and structural parameters of clots generated with fibrinogen purified from plasma of 
patients with cirrhosis and healthy volunteers. (A) Clotting time, (B) Clotting rate and (C) Changes in optical 
density of clots. (D) Permeability and (E) fiber density of clots. For turbidity studies, clotting was initiated 
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with 0.5 IU/mL thrombin at equal fibrinogen concentrations (1 mg/mL). For permeability and density 
studies, clotting was initiated with 0.5 IU/mL thrombin at equal fibrinogen and FXIII concentrations (1 
mg/mL and 7.3 µg/mL, resp.). (F) Representative LSCM image of fibrin mesh within a clot of a patient with 
Child B cirrhosis (left panel) and within a healthy volunteer clot (right panel) generated with purified 
fibrinogen (original magnification x630). Horizontal bars represent medians. Asterisks indicate significant 
differences in comparison with healthy volunteer values. *P<0.05; **P<0.01. 
Figure 6. Carbonyl content of fibrinogen purified from patients with cirrhosis and healthy volunteers. 
Protein carbonyl content was measured at equal fibrinogen concentrations (20 ʅg/mL). Horizontal bars 
represent medians. Asterisks indicate significant differences in comparison with healthy volunteer values. 
*P<0.05; **P<0.01. 
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